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Introduction
Th e use of renal replacement therapy (RRT) in ICU 
patients is increasing over the years [1-3]. Th is increase 
may be explained by a higher number of ICU patients 
with older age and increased comorbidity, as well as by a 
decrease of exclusion criteria for RRT, such as in special 
groups of ICU patients – for example, those with haemo-
dynamic instability and bleeding.
RRT encompasses a broad range of techniques (Table 1). 
A distinction can be made based on duration (inter mit-
tent, continuous), membrane permeability (high ﬂ ux, low 
ﬂ ux), diﬀ usion (haemodialysis) or convection (haemo ﬁ l-
tra tion) or a combination of these (haemo diaﬁ ltration), 
and equipment used (machine for regular haemodialysis, 
single-pass batch system or machines that are speciﬁ cally 
developed for continuous renal replace ment therapy 
(CRRT)).
Examples of continuous techniques include continuous 
haemodialysis, continuous venovenous haemoﬁ ltration 
(CVVH) and continuous venovenous haemodialﬁ ltration 
(CVVHDF). Intermittent therapies include haemodialysis 
(HD) with varying duration, ranging from short (2 to 
4  hours) to long (6 to 12  hours) as in sustained low-
eﬃ  ciency daily dialysis (or hybrid therapy, as it alterna-
tively named). Th is form of intermittent RRT can be 
performed with a classic dialysis machine, and its dialysis 
characteristics are intermediate between classic HD and 
CRRT. Blood ﬂ ow and dialysate ﬂ ows are decreased and 
the treatment time is increased up to 6 to 12 hours per 
day. Th is treatment allows better haemo dynamic toler-
ance and some hours per day oﬀ -machine, while the 
dialysis dose is maintained [4]. Intermittent haemodia ﬁ l-
tration can be applied as well, at least if online ultrapure 
water is available in the ICU.
Peritoneal dialysis (PD) is very seldom used for the 
treatment of acute kidney injury (AKI) in ICU patients. 
Data on the use of this modality are scarce (only 240 
adult patients were studied in three randomised studies) 
and come from developing countries. An initial report on 
PD demonstrated increased mortality of patients 
randomised to this RRT modality in the setting of AKI 
[5]. However, two other studies (one of which was 
published twice) found that the outcome of high-volume 
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and continuous PD was comparable with daily HD or 
CVVHDF in AKI [6-8]. An important limita tion of these 
last studies is that they excluded patients who died on 
day  1 after randomisation, thereby rendering a more 
favourable outcome.
Each of these RRT modalities has speciﬁ c charac teristics 
with implications for their use in speciﬁ c ICU patient groups.
Patients with increased risk for haemorrhage
Most modalities of RRT, with the exception of PD, need 
anticoagulation to prevent clotting in the extracorporeal 
circuit, thereby increasing the circuit life and dose of 
RRT and containing the cost for replacement of a new 
ﬁ lter and tubin. Th e downside of the use of anticoagu-
lants is the increased risk for haemorrhage. Th e most 
frequently used anticoagulant in ICU patients is unfrac-
tion ated heparin, followed by low molecular weight 
heparin and regional citrate anticoagulation [9].
No anticoagulation
In most patients, a 2-hour dialysis session can be per-
formed without anticoagulation; but in patients with 
thrombocytopaenia and coagulation disorders, even 
longer sessions up to CRRT can be performed without 
clotting. Th e use of heparin-coated membranes facilitates 
this session extension. Intermittent ﬂ ushing with saline 
can also postpone clotting. If haemoﬁ ltration is applied, 
predilution is preferred to prevent haemoconcentration 
in the circuit. In addition, in postdilution mode, the 
ﬁ ltration fraction – calculated as eﬄ  uent rate/plasma 
ﬂ ow rate – should be below 20 to 25%.
If no anticoagulation is allowed, catheter locks used to 
ﬁ ll up dialysis catheters between dialysis session should 
be heparin-free as leakage of heparin through the side 
holes is demonstrated. For that purpose, citrate-
containing solutions can be used as a catheter lock.
In the absence of contraindications, such as diverti cu-
litis or recent abdominal surgery, PD in theory can be an 
alternative RRT modality in patients at high risk for 
bleeding.
Regional anticoagulation with citrate or with 
heparin/protamine
Regional anticoagulation with citrate is based on its 
binding with calcium. Citrate, infused into the aﬀ erent 
bloodline, binds ionised calcium and hence blocks 
coagulation [10-12]. Th e removal of citrate is dependent 
on the dialysate ﬂ ow and/or ultraﬁ ltration rate. Citrate 
may enter the systemic circulation and can induce hypo-
calcaemia, resulting in cardiac problems. Calcium substi-
tution with a systemic calcium infusion is therefore 
nearly always necessary, especially in CRRT. Th e removal 
of citrate per minute is greater in dialysis compared with 
CVVH. Citrate anticoagulation is therefore theoretically 
safer in intermittent haemodialysis compared with CVVH, 
whereby less citrate is removed. Many diﬀ erent citrate 
schemes are used for predilution and postdilution CVVH, 
continuous venovenous haemodialysis (CVVHD) and 
CVVHDF, and we would like the reader to refer to speciﬁ c 
texts on this topic [11,12]. Haemodialysis with citrate can 
be performed with calcium-containing dialysate or with 
calcium-free dialysate, preferred for short and long 
sessions, respectively. In continuous modalities, and when 
using calcium-free dialysate, ionised calcium must be 
measured rigorously and calcium needs to be re-infused 
to prevent hypocalcaemia. Citrate accumulation can be 
monitored by the total to ionised calcium ratio. When 
this is above 2.5, the citrate dose should be decreased and 
calcium reinfused. In patients with reduced citrate 
metabolism, such as in liver failure and in patients with 
pre-existing hypocalcaemia and/or hypomagnesaemia, 
extra caution is warranted.
Regional citrate anticoagulation is increasingly used, 
and is currently recommended by the Kidney Disease: 
Improving Global Outcomes consensus group as the 
preferred anticoagulant for CRRT both in patients with 
and without increased bleeding risk (level of evidence 2B 
and 2C, indicating a suggestion based on low quality of 
evidence) (data not yet published; M Schetz, personal 
communi cation). Several studies have demonstrated the 
feasibility of this technique with diﬀ erent protocols. 
Regional citrate anticoagulation resulted in an increased 
ﬁ lter life in some studies, less bleeding complications, 
and in one study was even associated with increased 
survival when compared with low molecular weight 
heparin, although this could not be conﬁ rmed in another 
study where unfractionated heparin was the comparator 
[13-17].
Although regional anticoagulation was originally 
described with unfractionated heparin and protamine 
Table 1. Renal replacement therapy treatment modality options
Basis Modalities
Duration of therapy Intermittent versus continuous
Membrane permeability High fl ux versus low fl ux
Treatment technique Diff usion or haemodialysis versus convection or haemofi ltration versus a combination or haemodiafi ltration
Equipment Single-pass batch system versus regular haemodialysis machine versus continuous renal replacement therapy machine
Anticoagulation used No anticoagulation versus heparin (low molecular weight or unfractionated) versus citrate versus less frequently used 
 strategies (for example, prostacyclin or argatroban)
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[18,19], its use has decreased in parallel with the increas-
ing popularity of citrate. Protamine has several side 
eﬀ ects such as anaphylaxis, hypotension, cardiac depres-
sion, leukopaenia and thrombocytopaenia. Further, there 
is risk for a rebound anticoagulant eﬀ ect, due to the 
shorter half-life of protamine compared with heparin. 
Regional anticoagulation with heparin–protamine is 
therefore no longer recommended [20].
Other anticoagulation strategies
Prostaglandins and the synthetic protease inhibitor 
nafamostat mesilate inhibit platelet aggregation and 
adhesion. In CRRT, prostaglandin I2 and prostaglandin E1 
administered in a ﬁ xed dose resulted in less ﬁ lter clotting 
and less bleeding complications in a small prospective 
randomised study (n = 50 patients) [21]. Prostaglandin I2 
has also been successfully used in patients with combined 
AKI and acute liver failure, who were at increased risk for 
bleeding [22]. Prostaglandin induces vasodilation and 
therefore hypotension, however, and may also lead to 
increased intracranial hypertension and decreased 
cerebral perfusion pressure [23]. Th ese side eﬀ ects and 
the cost of this anticoagulation strategy hindered its 
widespread introduction and use.
Patients with heparin-induced thrombocytopaenia type II
When heparin-induced thrombocytopaenia type II is 
suspected or conﬁ rmed, the administration of un frac-
tion ated heparin and low molecular weight heparin is 
contraindicated. In that respect, catheter locks, rinsing 
solutions, dialyser membranes, catheters, and so forth, 
must also be heparin free. Besides regional citrate anti-
coagulation (or prostacyclin), the following anticoagu-
lants could be used in patients with heparin-induced 
thrombocytopaenia type II.
Argatroban, a direct thrombin inhibitor, is mainly 
hepatically metabolised with a short half-life of 
35  minutes in patients with end-stage kidney disease 
(ESKD). Th e activated clotting time and the activated 
partial thromboplastin time can be used for monitoring. 
Only minor extracorporeal clearance with high-ﬂ ux 
membranes is demonstrated. Argatroban, due to its short 
half-life, is a safe anticoagulant in patients with renal 
failure without hepatic impairment. In patients with 
multiple organ failure, however, one-tenth of the usual 
dose without an initial bolus is recommended, depending 
on hepatic function [24].
Diﬀ erent argatroban dosing regimens have been 
described for diﬀ erent RRT modalities. A proposed dose 
in chronic haemodialysis patients is a 250  μg/kg bolus 
followed by continuous infusion of 2 μg/kg/minute [25]. 
In ICU patients treated with CRRT, it is recommended to 
administer a loading dose of 100  μg/kg argatroban 
followed by a maintenance infusion rate (μg/kg/minute) 
that is adjusted for severity of illness (measured by either 
2.15  – 0.06  × Acute Physiology and Chronic Health 
Evaluation II score, or by 2.06 – 0.03 × Simpliﬁ ed Acute 
Physiology Score II) and liver function, assessed by the 
indocyanine green disappearance rate (–0.35  + 0.08  × 
indocyanine green disappearance rate) [26]. For ICU 
patients treated with predilution intermittent venovenous 
haemodialysis, recommendations are a loading dose of 
75  μg/kg followed by a continuous infusion of 0.4 to 
0.6 μg/kg/minute until 20 minutes before termination of 
RRT [27].
Despite clinical use of argatroban in RRT, it should be 
mentioned that this is an oﬀ -label use for this drug.
Fondaparinux is a synthetic heparin analogue that can 
be used in patients with heparin-induced thrombo cyto-
paenia type II. In the absence of renal function, a single 
intravenous dose of 2.5 mg can maintain dialysis circuit 
patency provided that low-ﬂ ux membranes are used [28]. 
Owing to its renal clearance, therapeutic anti-factor Xa 
activity is still demonstrated 48  hours after adminis-
tration of 2.5 mg fondaparinux. Removal of fondaparinux 
is enhanced by the use of high-ﬂ ux membranes. In ICU 
patients, caution is recommended for this anticoagulant 
considering its long half-life and the high bleeding risk, 
and/or the frequent need for surgical intervention or 
invasive procedures. Also, heparin-induced thrombo-
cyto paenia is an oﬀ -label indication for fondaparinux.
Lepirudin, or recombinant hirudin, is a direct thrombin 
inhibitor and can also be used in patients with heparin-
induced thrombocytopaenia type II. In dialysis patients, a 
single intravenous dose of 0.08  mg/kg is recommended 
[29]. Because of its renal clearance, this dose results in 
sustained anticoagulation. Dialyser clearance depends on 
the membrane characteristics. High-ﬂ ux membranes allow 
ﬁ ltration of lepirudin, with the highest sieving coeﬃ  cient 
for polysulfone (0.97) and lesser sieving coeﬃ  cients for 
polymethylmethacrylate and polyarylethersulfone (0.75 
and 0.73, respectively). Low-ﬂ ux membranes do not ﬁ lter 
lepirudin [30]. Dependent on the dialysis frequency, the 
dialysis membrane, and the activated partial 
thromboplastin time, measured before the start of the 
dialysis session, a reduced dose should be used from the 
second dialysis. Because of its prolonged half-life (52 
hours), lepirudin is not an anticoagulant of choice in the 
intensive care patient with AKI.
Patients with severe haemodynamic instability
Haemodynamically unstable patients should be treated 
carefully, which can be achieved either by CVVH(D), 
sustained low-eﬃ  ciency daily dialysis or continuous HD. 
In many haemodynamically unstable patients, HD can be 
performed when speciﬁ c precautions are taken [31,32]. 
Th ese precau tions include: less aggressive ultraﬁ ltration, 
increasing the treatment time in CRRT and daily 
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treatment in intermittent HD, eventually using blood 
volume measure ments to guide ultraﬁ ltration; increasing 
dialysate sodium and calcium concentrations to respec-
tively 145 mmol/l and 1.5 mmol/l; adapting the dialysate 
temperature to obtain isothermic dialysis; connecting 
aﬀ erent and eﬀ erent bloodlines simultaneously at the 
start of the procedure; using low blood ﬂ ow (<150  ml/
minute) and low dialysate ﬂ ows; using biocompatible 
membranes; and using (ultra)pure water [31].
An argument in favour of CRRT in haemodynamically 
unstable patients is that solute control is more constant. 
Th is factor may be of particular beneﬁ t in patients with 
severe lactic acidosis, where RRT may help to stabilise 
the haemodynamic status by correction of blood pH. In 
patients with severe lactic acidosis, intermittent therapy 
will only oﬀ er a temporal improvement of blood pH – 
between treatments there will be recurrent acidosis, with 
its untoward haemodynamic consequences.
In summary, patients with severe haemodynamic 
instability are best treated with CRRT in order to allow 
removal of extravascular ﬂ uid and to maintain a stable 
blood pH.
A more elaborate discussion on the choice between 
CRRT and HD is presented in another publication in this 
topic series [33].
Patients with intracranial hypertension or cerebral 
oedema
Patients with cerebral oedema or intracranial hyper ten-
sion have decreased or absent autoregulation of cerebral 
blood ﬂ ow. A decrease in systemic blood pressure, as may 
occur during RRT, will therefore lead to decreased 
cerebral blood ﬂ ow and to cerebral ischaemia, which will 
consequently lead to more oedema [34]. Continuous 
arteriovenous haemoﬁ ltration has been proven to better 
maintain cerebral blood ﬂ ow in patients with acute liver 
failure and cerebral oedema compared with intermittent 
dialysis [35,36]. Th ese ﬁ ndings have been extrapolated to 
treat ment recommendations for patients with other 
causes of cerebral oedema and to newer modalities of 
CRRT such as CVVH or CVVHD [37,38].
Another argument in favour of a low eﬃ  cient CRRT is 
that this therapy will seldom be complicated with acute 
and important tonicity changes of the systemic 
circulation. Because intermittent HD is a very eﬃ  cient 
RRT modality, these changes may occur after a session of 
HD. A decrease in serum osmolality will subsequently 
lead to water uptake by the cells, and to development of 
cellular oedema [39]. Intracranial pressure may therefore 
increase after HD.
If a patient is also at increased risk for intracranial 
haemor rhage, such as after traumatic brain injury, RRT 
should be administered without anticoagulation or with 
regional citrate anticoagulation. Th eoretically, PD can be 
considered as an alternative. Concerns on this modality 
are the eﬃ  cacy and the eﬀ ects on intra-abdominal 
pressure. Th e intra-abdominal pressure may increase 
secon dary to infusion of PD ﬂ uid in the abdominal cavity, 
which may have diverse eﬀ ects on intracranial pressure 
and cerebral perfusion [40,41]. Increased abdominal 
pressure may translate into increased intracranial 
pressure. Further, intra-abdominal hypertension may also 
decrease systemic preload and increase afterload, leading 
to lower blood pressure and decreased cerebral perfusion 
pressure.
Patients with hyponatraemia
When chronic hyponatraemia is corrected rapidly, 
patients may develop osmotic demyelination syndrome 
[42,43], a condition with most irreversible brain damage. 
Th erefore, in asymptomatic patients with chronic 
hyponatraemia, the sodium concentration should be 
increased slowly, with a maximum increase of 10 to 
12  mmol/l during the ﬁ rst 24  hours and of 18  mmol/l 
during the ﬁ rst 48 hours of treatment [44]. High serum 
urea concentration may protect the brain against the 
development of osmotic demyelination [45,46]. An 
explanation for this may be the slow diﬀ usion of urea 
over the blood–brain barrier. Dialysis will decrease 
serum urea rapidly, but urea that has accumulated in 
brain cells will decrease only slowly. Th is diﬀ erence will 
create a blood–brain gradient of urea, and will lead to 
accumulation of water in brain cells and a slower decline 
of cell volume, which is the mechanism that leads to 
osmotic demyelination. Low-eﬃ  ciency RRT such as 
CVVH is recom mended in these patients.
Some authors have recommended the use of replace-
ment ﬂ uid with reduced sodium concentration. Th is can 
be established by adding sterile water to the replacement 
ﬂ uid bag [47]. Diluting replacement ﬂ uid will also result 
in decreased potassium and bicarbonate concentrations, 
and therefore may induce hypokalaemia and acidosis. 
Th ese patients therefore need frequent follow-up of 
sodium and potassium concentrations and blood pH. 
During treatment, increasing plasma sodium concen-
trations may require less diluted replacement ﬂ uid; 
patients may also have need for additional potassium or 
bicarbonate infusion. Because this procedure is poten tially 
error prone, and may lead to contamination of sterile 
replacement ﬂ uid, an alternative strategy is intravenous 
infusion of hypotonic ﬂ uid (for example, 5% glucose).
Patients with high serum urea concentration
When serum urea is high (typically >175 mg/dl) patients 
are at risk for developing dialysis disequilibrium syn-
drome, a neurological condition characterised by nausea 
and headache. Th e exact mechanism of dialysis disequili-
brium is uncertain. A sudden decrease of serum 
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osmo lality and slower decrease of (brain) cell osmolality 
with resultant increase of cellular water content is the 
most probable cause. A change in intracellular pH and 
accu mulation of organic osmolites are also mentioned as 
a possible cause for this condition. Preventive measures 
include initiation RRT with ultraﬁ ltration followed by 
dialysis, which will increase plasma osmolarity and so 
prevent development of cerebral oedema and dialysis 
disequilibrium. Decreasing the dose of dialysis will also 
prevent important changes of urea concentration, and so 
prevent dialysis disequilibrium. Th is can be achieved by 
shortening the ﬁ rst RRT session when intermittent 
modalities are used (2  hours), decreasing blood ﬂ ow 
(<200 ml/minute), using a small less eﬃ  cient dialyser, or 
using low-dose CVVH (for example, ultraﬁ ltration rate 
<20 ml/kg/hour). A urea reduction ratio of 0.4 to 0.45 or 
a urea clearance over time of the dialysis session 
corrected for volume of distribution (Kt/V) of 0.6 to 0.7 
has been proposed. Administration of osmotic agents 
such as mannitol (1  g/kg intravenously per dialysis 
session) may also be of help. Finally, an increased 
dialysate sodium concentration (143 to 146  mmol/l) is 
also recommended in patients at risk [48-50].
Patients with acute or acute on chronic liver failure
Th ere are several aspects that deserve special attention in 
patients with liver failure and AKI.
Encephalopathy and cerebral oedema
Patients with acute liver failure and encephalopathy are 
very likely to have cerebral oedema, especially when the 
time between occurrence of jaundice and encephalopathy 
is short; for example, as in fulminant liver failure, deﬁ ned 
by a time delay between icterus and encephalopathy of 
less than 2 weeks [37,51]. Th ese patients are at increased 
risk for increased intracranial pressure and brain stem 
herniation. One should therefore apply the principles for 
prevention of deterioration of intracranial pressure as 
described above. In summary, CRRT with special 
attention for haemo dynamic stability and maintenance of 
cerebral perfusion pressure is warranted.
Hyponatraemia
Patients with liver failure often experience chronic 
hyponatraemia. Hence, special attention should be given 
to a slow increase of serum sodium, as discussed above.
Hepatorenal syndrome
Patients with acute and acute on chronic liver failure may 
develop AKI as a consequence of hepatorenal syndrome. 
Especially in patients with acute on chronic liver failure 
this is an end stage of the process of water retention and 
increased catecholamine stress, characterised by hypo-
natraemia and ascites [52].
A small prospective randomised study suggests that 
treatment with artiﬁ cial liver support may improve 
survival in these patients [53]. Th is study was under-
powered (n  =  13 patients), however, and the control 
popu lation was not treated with vasopressin analogues, 
which is currently the standard of care. A large pros-
pective randomised study comparing the standard of care 
for liver dialysis with that of the Prometheus liver dialysis 
system (Fresenius Medical Care, Bad Homburg, Germany) 
in patients with acute on chronic liver failure recently 
found in subanalysis that patients with hepatorenal 
syndrome treated with Prometheus liver dialysis had 
better survival [54]. Th is study is currently only presented 
as an abstract, so we can only discuss preliminary results.
Th ere are no data that support the use of one speciﬁ c 
RRT modality above another for hepatorenal syndrome, 
although generally less aggressive modalities such as 
sustained low-eﬃ  ciency daily dialysis or CRRT will be 
used most.
Coagulation abnormalities
Patients with liver failure have decreased production of 
coagulation factors II, V, VII, IX, X and XI, thrombo-
cytopaenia and decreased thrombocyte function [55,56]. 
Th is will lead to decreased coagulation. Many patients 
with severe liver failure can therefore undergo RRT 
without anticoagulation. However, decreased production 
of protein C, protein S and antithrombin III, increased 
concentrations of factor VIII, von Willebrand factor and 
heparin cofactor II, and a decreased concentration of 
plasminogen will lead to increased coagulation, despite 
abnormal coagulation tests. Coagulation tests can there-
fore be misleading and, despite abnormal tests, ﬁ lter 
clotting may occur. Monitoring the coagulation status 
with func tional haemostasis monitoring devices such as 
thrombo elastography or Sonoclot (Sienco Inc., Arvada, 
Colorado, USA), which measure the individual contri-
bution of coagulation by platelets and coagulation 
factors, and ﬁ brinolysis may be of help to better under-
stand the coagulation status of these patients.
Patients with severe lactic acidosis
Th e treatment for lactic acidosis should be aimed at 
correcting the cause. However, as severe acidosis may in 
itself lead to profound systemic hypotension, RRT is 
sometimes used as a bridge until correction of the 
underlying cause, especially in patents who also have AKI 
[57]. RRT may correct blood pH, by removing lactic acid 
and through administration of bicarbonate from the 
dialysate. Con tinuous modalities are preferred to prevent 
intra dialytic rebound, and dialysis is more eﬃ  cient in 
removing small molecules as lactate [58,59].
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Patients with congestive heart failure
Patients with decompensated heart failure and diuretic 
resistance, without AKI, can beneﬁ t from isolated 
ultraﬁ ltration [60,61]. When these patients are haemo-
dynamically unstable, the ultraﬁ ltration rate should be 
limited by increasing the treatment time. Th is limitation 
can be achieved by CRRT or hybrid therapy. PD is also 
used for ﬂ uid removal in patients with congestive heart 
failure and ESKD. However, ﬂ uid removal is less 
predictable com pared with extracorporeal ultraﬁ ltration 
[62,63].
Special attention should be given to patients with 
congestive heart failure and (chronic) hyponatraemia (see 
the discussion on hyponatraemia above).
Patients with burn injury
On average, 3% of patients with severe burn injury are 
treated with RRT for AKI [64]. Patients with burn injury 
and AKI often have large wounds and repetitive surgical 
interventions with increased risk for bleeding.
Another issue in burn patients is accumulation of 
iodine. Burn patients treated with topical povidone–
iodine may have elevated iodine concentrations, secon-
dary to increased absorption in combination with 
hampered renal excretion. Th is can lead to metabolic 
acidosis, AKI, and heart conduction abnormalities, 
eventually leading to heart block. Th e molecular weight 
of iodine is 253; hence the dialyser clearance during high-
ﬂ ux dialysis is comparable with that of small solutes such 
as urea. Intercompartmental clearance is low, however, so 
long treatment times are mandatory [65]. Protracted 
high-ﬂ ux haemodialysis or haemodiaﬁ ltration, with high 
blood and dialysate ﬂ ow, is therefore the treatment of 
choice to remove iodine.
Patients with accidental hypothermia
Consensus exists about cardiopulmonary bypass as the 
treatment of choice in cases of severe accidental hypo-
thermia with cardiac arrest. In settings where cardio-
pulmonary bypass is not available, or in haemo-
dynamically stable patients, HD is a valuable alternative 
[66]. Setting dialysate ﬂ ow and temperature to their 
maximum optimises the eﬃ  ciency of warming. Blood 
ﬂ ow and the membrane surface should also be optimised. 
HD can be started without exogenous anticoagulation 
because hypothermia is associated with coagulopathy.
Patients with intoxications
Th e use of RRT in the treatment of intoxicated patients 
has decreased over recent years. Reasons for this decline 
are diverse. Some intoxications, such as with paraquat 
and theophyllin, are nowadays less frequent in the 
western world. Other intoxications, such as with 
methanol and ethylene glycol, are often treated with 
fomepizole. At present, the most frequently encountered 
intoxications treated with RRT are caused by lithium, 
methanol, ethylene glycol and iodine. Rare intoxications 
that should in special indications be treated with haemo-
dialysis include valproic acid, isoniazid and metformin 
[67]. Th e mainstay for treatment of salicylate intoxication 
remains alkalinisation of blood and urine. In patients 
with severe salicylate intoxication and in patients 
presenting with severe ﬂ uid overload and/or pulmonary 
or cerebral oedema, however, HD should be used to 
eﬀ ectively remove salicylate from blood [68,69].
With the introduction of high-ﬂ ux membranes and 
haemo diaﬁ ltration, haemoperfusion with charcoal cart-
ridges has lost importance.
Th e lack of residual endogenous clearance, sometimes 
caused by the intoxication itself, will accelerate the 
decision to start dialysis. Examples include AKI in 
patients with lithium, iodine or ethylene glycol intoxi-
cations. If the molecular weight of a toxin is low and 
protein binding is limited, dialyser clearance is expected 
to be high. Th is is a prerequisite for eﬃ  cient removal. Th e 
body clearance depends on the compartmental behaviour. 
If the distribution is multicompartmental, with slow 
equili bration between the diﬀ erent compart ments, reb-
ound can ensue. In these cases, long dialysis times are 
necessary. Because of this latter reason and because of 
the availability of alternative treatment (digoxin-speciﬁ c 
Fab fragments), digoxin intoxications are seldom treated 
by haemodialysis.
Our preference is to apply haemodialysis (mostly high 
ﬂ ux) with high blood ﬂ ow (250 to 300  ml/minute) and 
high dialysate ﬂ ow (500 ml/minute) and a long treatment 
time or even continuously in order to optimise both 
dialyser and body clearance. For larger solutes, protracted 
or continuous online haemodiaﬁ ltration is more eﬃ  cient. 
CVVH or CVVHD results in much less dialyser clearance 
because of absent or limited dialysate ﬂ ow. Patients with 
lithium intoxication without renal failure should 
preferably not be treated with a single-pass batch system, 
as premature mixing of dialysate has been documented in 
the absence of uraemic solutes [70]. In these patients, 
haemodialysis with a conventional haemodialysis 
machine is recommended.
Chronic haemodialysis patients admitted to 
the ICU
Chronic haemodialysis patients represent a minority of 
ICU patients. In a tertiary care centre in the USA, 3.7% of 
ICU patients were chronic haemodialysis patients [71]. 
Other studies found that 11 to 12% of all patients treated 
with RRT in the ICU are chronic dialysis patients [72,73]. 
Th e main reasons for ICU admission are sepsis and 
cardiovascular complications, which are com parable with 
AKI patients [72,73]. Instead of the regular outpatient 
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dialysis schedule of 4 hours of dialysis three times weekly, 
RRT during the ICU stay should be adapted towards the 
current needs of the patient. Daily, protracted dialysis 
can easily be performed through the arteriovenous 
ﬁ stula. Staﬀ  should be extremely vigilant in keeping this 
arteriovenous ﬁ stula patent. Th ey should therefore be 
advised against using the arm with the arteriovenous 
ﬁ stula for blood sampling, arterial line insertion or non-
invasive blood pressure measurement. Needling of this 
arteriovenous ﬁ stula should only be performed by an 
experienced dialysis nurse. A temporary dialysis catheter 
is preferred when a continuous technique is applied.
Renal replacement therapy during surgery
Occasionally, haemodialysis is performed during surgery. 
Because liver transplantation in patients with renal 
impair ment can be associated with severe hyperkalaemia, 
especially during reperfusion, intraoperative dialysis 
should be considered. Unstable patients with acidosis 
and persistent electrolyte disturbances may also beneﬁ t 
from a continuation of the dialysis in the operation room. 
Special attention should be paid to the temperature of the 
dialysate, to avoid cooling of the patient. If no water 
treatment is available in the operation room, haemo-
dialysis can be performed with a single-pass batch 
system. Anticoagulation is mostly contraindicated, or in 
the case of liver transplantation is not needed. If 
necessary, a heparin-coated membrane can be used [74]. 
During liver transplantation, citrate may accumulate 
when regional citrate anticoagulation is used. Th e citrate 
load is often already elevated in these patients due to the 
adminis tration of fresh frozen plasma and packed cells. 
We therefore do not recommend citrate anticoagulation 
in these patients.
Extracorporeal therapy in sepsis
Continuous venovenous haemofi ltration
Two prospective randomised studies evaluated the use of 
standard CVVH compared with the standard of care in 
patients with severe sepsis [75,76]. Th e rationale was that 
inﬂ ammatory mediators were removed at a constant rate 
in the CVVH intervention group, and that the inﬂ am ma-
tory process could therefore be halted. Neither study 
could demonstrate that CVVH led to decreased serum 
concentrations of mediators, or to improvement of organ 
dysfunction. In fact, the most recent study was 
discontinued after an interim analysis on 76 patients 
demonstrated more organ dysfunction and more severe 
organ dysfunction in patients randomised to CVVH 
compared with the standard of care [76].
High-volume haemofi ltration
Observational data by Ratanarat and colleagues and by 
Honore and colleagues demonstrated that short-term 
high-volume haemoﬁ ltration – 6 to 8 hours of CVVH at 
85  ml/kg/hour followed by 16 to 18  hours of CVVH at 
35  ml/kg/hour [77], and ultraﬁ ltration of 35  l during a 
4-hour period followed by conventional CVVH [78] – 
was associated with better outcomes than compared with 
historic controls [77,78]. In the High Volume on Intensive 
Care (IVOIRE) study, septic study patients were random-
ised to high-volume haemoﬁ ltration (70  ml/kg/hour for 
96  hours) or to standard-dose CVVH (35  ml/kg/hour). 
Th e study was recently stopped after interim analysis, but 
was not yet published at the time of this review. Th e 
results will inform us on the exact place of this technique 
for treatment of sepsis patients.
Polymyxin-B haemoperfusion
Polymyxin-B bound to a membrane is a compound that 
eﬃ  ciently binds endotoxin, a component released from 
the cell membrane of Gram-negative bacteria. Endotoxin 
is a crucial component in the inﬂ ammatory cascade 
follow ing Gram-negative infection. Several smaller 
studies that were bundled in a meta-analysis and a recent 
small prospective randomised study in patients with intra-
abdominal sepsis demonstrated that binding endotoxin 
with polymyxin-B haemoperfusion may improve 
haemodynamics and organ function at 72 hours, and may 
improve short-term (28-day) mortality in sepsis patients 
[79,80]. Th ese results are promising, but the dataset is 
still too small to adopt this therapy in routine practice.
Coupled plasma fi ltration and absorption combined with 
haemodialysis.
Coupled plasma ﬁ ltration and absorption also targets 
diminishing the inﬂ ammatory process, by removing 
inﬂ ammatory mediators through absorption. For this 
technique, blood is ﬁ ltered by a plasma ﬁ lter. Plasma that 
is produced by the plasma ﬁ lter is run through an 
absorption ﬁ lter, reinfused into the circuit, and 
subsequently ﬁ ltered by a high-permeable polysulfone 
haemoﬁ lter. Results from a small pilot crossover study in 
10 patients with severe septic shock demonstrated that 
this technique improved haemo dynamics during the 
10-hour plasma ﬁ ltration and absorption session 
compared with CVVHDF [81]. Responsiveness of white 
blood cells to stimulation with lipopolysaccharide was 
also normalised after treatment with coupled plasma 
ﬁ ltration and absorption. A prospective randomised 
study on this technique was concluded in Italy recently, 
but the results have not yet been published.
Conclusions
Especially in ICU patients who have severe AKI, 
treatment with RRT requires balancing the pros and cons 
of diﬀ erent options and modalities. Special groups of 
ICU patients that deserve extra consideration are, for 
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example, patients with coagulation abnormalities or with 
increased risk for bleeding, such as after surgery, patients 
with severe haemodynamic instability, liver failure 
patients and patients with hyponatraemia. Exact and 
speciﬁ c guidelines for RRT in these patients are not 
available for most clinical situations.
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